Profile data is unavailable for this security.
About the company
Amplifon SpA is an Italy-based company active in the hearing care retail market. The Company provides personalized solutions and customer care to hearing-impaired people. It offers a wide range of services from diagnosing hearing difficulties, to fitting, servicing and maintaining hearing aids. The Company is organized in three geographical operating segments: Europe, Middle East and Africa - EMEA - (Italy, France, The Netherlands, Germany, the United Kingdom, Ireland, Spain, Portugal, Switzerland, Belgium, Luxemburg, Hungary, Egypt, Turkey, Poland and Israel), Americas (USA, Canada, Chile, Argentina, Ecuador, Colombia, Panama and Mexico) and Asia-Pacific (Australia, New Zealand, India and China).
- Revenue in EUR (TTM)2.26bn
- Net income in EUR155.14m
- Incorporated--
- Employees14.38k
- LocationAmplifon SpAVia Ripamonti 133MILANO 20141ItalyITA
- Phone+39 2574721
- Fax+39 257300033
- Websitehttps://www.amplifon.com/
More ▼
Mergers & acquisitions
| Acquired company | AMP:MIL since announced | Transaction value |
|---|---|---|
| Miracle-Ear Centers of Arkansas LLC | 7.09% | -- |
| Las Davis Enterprises Inc | 7.09% | -- |
| Hearing Pro Inc | 7.09% | -- |
| Audical SRL | 6.62% | -- |
| Living Sounds Hearing Centre | 11.19% | -- |
Data delayed at least 15 minutes, as of May 06 2024 08:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambu A/S | 656.74m | 31.92m | 3.68bn | 4.70k | 129.41 | 5.73 | 46.14 | 5.60 | 0.9014 | 0.9014 | 18.71 | 20.36 | 0.7075 | 2.00 | 7.26 | 1,060,875.00 | 3.44 | 3.81 | 3.97 | 4.62 | 56.97 | 59.37 | 4.86 | 5.43 | 1.30 | 7.20 | 0.1038 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| GN Store Nord A/S | 2.44bn | 71.88m | 4.05bn | 7.05k | 54.09 | 2.92 | 13.30 | 1.66 | 3.70 | 3.70 | 127.04 | 68.44 | 0.6139 | 3.00 | 4.73 | 2,541,382.00 | 1.94 | 4.91 | 3.22 | 7.44 | 50.50 | 53.29 | 3.16 | 6.82 | 0.4118 | 2.50 | 0.5582 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
| Ypsomed Holding AG | 521.96m | 74.32m | 4.67bn | 2.20k | 62.78 | 7.93 | 30.45 | 8.95 | 5.31 | 5.31 | 37.31 | 42.03 | 0.5888 | 4.92 | 5.75 | 247,016.00 | 8.38 | 4.44 | 12.70 | 6.77 | 32.04 | 26.95 | 14.24 | 6.87 | 0.5577 | 30.61 | 0.2614 | 18.54 | 7.02 | 1.31 | 121.92 | -0.3034 | 20.32 | -1.47 |
| Getinge AB | 2.77bn | 196.14m | 5.07bn | 11.86k | 27.70 | 1.96 | 14.91 | 1.83 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 11.47 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 905.64m | 158.11m | 5.72bn | 4.65k | 36.16 | 7.95 | 27.62 | 6.31 | 1.05 | 1.05 | 6.01 | 4.78 | -- | -- | -- | 194,928.30 | -- | -- | -- | -- | 35.23 | -- | 17.48 | -- | 1.08 | -- | 0.094 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| ConvaTec Group PLC | 1.99bn | 121.12m | 6.18bn | 10.13k | 51.10 | 3.93 | 19.26 | 3.10 | 0.0506 | 0.0506 | 0.8321 | 0.6583 | 0.5865 | 2.57 | 6.14 | 168,614.90 | 3.57 | 2.36 | 4.18 | 2.73 | 56.04 | 55.03 | 6.08 | 4.34 | 0.8835 | 2.65 | 0.4367 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| Amplifon SpA | 2.26bn | 155.14m | 7.14bn | 14.38k | 45.74 | 6.47 | 16.93 | 3.16 | 0.6898 | 0.6898 | 10.02 | 4.88 | 0.6219 | 20.99 | 10.38 | 157,179.50 | 4.27 | 4.31 | 6.16 | 5.81 | 23.56 | 59.01 | 6.86 | 7.28 | 0.4519 | 6.31 | 0.5795 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Carl Zeiss Meditec AG | 2.09bn | 276.75m | 8.75bn | 4.82k | 31.56 | -- | 107.15 | 4.18 | 3.10 | 3.10 | 23.45 | -- | -- | -- | -- | 434,177.70 | -- | 9.56 | -- | 11.72 | 57.35 | 57.84 | 13.28 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| Demant A/S | 3.01bn | 342.25m | 9.63bn | 21.62k | 28.40 | 7.74 | -- | 3.20 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Smith & Nephew plc | 5.16bn | 244.47m | 10.15bn | 18.45k | 41.46 | 2.09 | 11.54 | 1.97 | 0.2402 | 0.2402 | 5.07 | 4.77 | 0.5562 | 0.7522 | 4.33 | 239,735.90 | 2.64 | 4.10 | 3.29 | 4.99 | 68.82 | 71.39 | 4.74 | 8.02 | 0.72 | 4.84 | 0.3715 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | -8.12 |
Data as of May 06 2024. Currency figures normalised to Amplifon SpA's reporting currency: Euro EUR
13.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 5.99m | 2.65% |
| Comgest SAas of 31 Jan 2024 | 5.07m | 2.24% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 4.56m | 2.01% |
| Allianz Global Investors GmbHas of 31 Jan 2024 | 3.12m | 1.38% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 2.61m | 1.15% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 2.14m | 0.95% |
| Norges Bank Investment Managementas of 21 Apr 2023 | 2.06m | 0.91% |
| Cr�dit Mutuel Asset Management SAas of 31 Mar 2023 | 1.99m | 0.88% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 1.74m | 0.77% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 1.52m | 0.67% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
